drugset / Trial / NCT00935753

Trial of Kuvan in Lesch-Nyhan Disease

NCT00935753

NaSingle-groupOpen-labelTreatment

Summary

To assess the possibility that treatment with Kuvan (a form of tetrahydrobiopterin) will lessen the abnormal behavior and/or neurology commonly found in Lesch-Nyhan disease (LND); to assess biochemical changes as measured in blood and urine.

Timeline

Start
2009-04
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject sapropterin Unknown 20 mg/kg Oral

Indications